共 50 条
- [1] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFINBLOOD CANCER JOURNAL, 2022, 12 (04)Nooka, Ajay K.Kaufman, Jonathan L.Rodriguez, CesarJakubowiak, AndrzejEfebera, YvonneReeves, BrandiWildes, TanyaHolstein, Sarah A.Anderson, Larry D., Jr.Badros, AshrafShune, LeylaChari, AjaiPei, HuilingCortoos, AnnelorePatel, SharmilaBartlett, J. BlakeVermeulen, JessicaLin, Thomas S.Richardson, Paul G.Voorhees, Peter
- [2] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialBLOOD, 2020, 136 (08) : 936 - 945Voorhees, Peter M.Kaufman, Jonathan L.Laubach, JacobSborov, Douglas W.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Holstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Murphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, Thomas S.Richardson, Paul G.
- [3] Daratumumab plus Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFINCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E353 - E354Voorhees, PeterKaufman, Jonathan L.Laubach, JacobSborov, DouglasReeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, LucianoAnderson, LarryNathwani, NityaShah, NinaEfebera, YvonneCostello, CaitlinJakubowiak, AndrzejWildes, TanyaOrlowski, Robert Z.Shain, Kenneth H.Cowan, AndrewMurphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, ThomasRichardson, Paul G.
- [4] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN studyFUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456Nooka, Ajay K.Kaufman, Jonathan L.Rodriguez, CesarJakubowiak, AndrzejEfebera, YvonneReeves, BrandiWildes, TanyaHolstein, Sarah A.Anderson Jr, Larry D.Badros, AshrafShune, LeylaChari, AjaiPei, HuilingCortoos, AnnelorePatel, SharmilaLin, Thomas S.Richardson, Paul G.Voorhees, Peter
- [5] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFINCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156Nooka, AjayKaufman, JonathanRodriguez, CesarJakubowiak, AndrzejEfebera, YvonneReeves, BrandiWildes, TanyaHolstein, SarahAnderson, LarryBadros, AshrafShune, LeylaChari, AjaiPei, HuilingCortoos, AnnelorePatel, SharmilaLin, ThomasUsmani, SaadRichardson, PaulVoorhees, Peter
- [6] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of GriffinBLOOD, 2021, 138Anderson, Larry D., Jr.Kaufman, Jonathan L.Laubach, Jacob P.Sborov, Douglas W.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, Rebecca W.Costa, Luciano J.Nathwani, NityaShah, NinaBumma, NareshHolstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Pei, HuilingCortoos, AnnelorePatel, SharmilaBartlett, J. BlakeVermeulen, JessicaLin, Thomas S.Voorhees, Peter M.Richardson, Paul G.
- [7] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFINCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309Nooka, Ajay K.Kaufman, Jonathan L.Rodriguez, CesarJakubowiak, AndrzejShune, LeylaBadros, AshrafChari, AjaiRichardson, Paul G.Pei, HuilingUkropec, JonVermeulen, JessicaHoehn, DanielaLin, Thomas S.Voorhees, Peter M.
- [8] Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study UpdateBONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 127 - 128Voorhees, Peter M.Kaufman, Jonathan L.Laubach, JacobSborov, Douglas W.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Murphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, JessicaDe Boer, CarlaHoehn, DanielaLin, Thomas S.Richardson, Paul G.
- [9] Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S125 - S126Silbermann, RebeccaLaubach, JacobKaufman, JonathanSborov, DouglasReeves, BrandiRodriguez, CesarChari, AjaiCosta, LucianoAnderson, LarryNathwani, NityaShah, NinaBumma, NareshCostello, CaitlinJakubowiak, AndrzejOrlowski, RobertShain, KenGries, KatharinePei, HuilingCortoos, AnnelorePatel, SharmilaMatt, KathrynLin, ThomasUsmani, SaadVoorhees, PeterRichardson, Paul
- [10] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary AnalysisAMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S31 - S31Chari, AjaiVoorhees, Peter M.Kaufman, Jonathan L.Laubach, JacobSborov, Douglas W.Reeves, BrandiRodriguez, CesarSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Ander J.Murphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, Thomas S.Richardson, Paul G.